Investigational drug SPN-820, which activates the mTORC1 pathway, failed to significantly reduce depressive symptoms compared ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

Antidepressants like SSRIs can be life-saving for people struggling with depression, OCD, anxiety and other mental health ...

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

Groundbreaking research shows psilocybin therapy equals traditional antidepressants in treating depression with potential ...

Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset missed its primary endpoint in a phase 2b trial. SPN-820 failed to improve ...

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...

Supernus Pharma has suffered a blow to its R&D pipeline after a candidate for treatment-resistant depression failed a ... on the development of the drug, which is also known as NV-5138, paying ...

In the second episode of The Deep End, listeners hear what it’s like to live with severe depression and the backstory of an experimental treatment.

“This bill would require the Alabama Medicaid Agency to cover screening and would also regulate how Medicaid covers prescription drugs used to treat postpartum depression,” the legislation states.

Zoloft (sertraline) has interactions with many types of medications, including other antidepressants, amphetamines, blood ...